Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Microorganisms|July 27, 2024
Immunological and Safety Considerations When Selecting the Dose Formulation of a Purified Inactivated Zika Virus Vaccine (PIZV)Camilo J Acosta, Francesco Nordio, Eloi Kpamegan, et al.
Microorganisms|June 27, 2024
Predicting Efficacy of a Purified Inactivated Zika Virus Vaccine in Flavivirus-Naïve Humans Using an Immunological Correlate of Protection in Non-Human PrimatesCamilo J Acosta, Francesco Nordio, David A Boltz, et al.
International Journal of Molecular Sciences|November 13, 2021
Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue VirusEduardo J M Nascimento, Brooke Norwood, Allan Parker, et al.
The Journal of Infectious Diseases|April 3, 2025
Anti-Dengue Virus Antibody Avidity Correlates with Protection Against Symptomatic Dengue Virus InfectionIsamu Tsuji, David Dominguez, Jonathan Hernandez, et al.
Vaccine|August 31, 2015
Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigsGregory M Glenn, Louis F Fries, Gale Smith, et al.
The Journal of Infectious Diseases|August 12, 2015
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing AgeGregory M Glenn, Louis F Fries, D Nigel Thomas, et al.
Vaccine|July 30, 2013
Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virusGale E Smith, David C Flyer, Ramadevi Raghunandan, et al.
Immunity & Ageing : I & A|April 18, 2017
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adultsLouis Fries, Vivek Shinde, Jeffrey J Stoddard, et al.
The Journal of Infectious Diseases|December 3, 2022
Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement SystemEduardo J M Nascimento, Brooke Norwood, Eloi Kpamegan, et al.
Vaccine|November 17, 2012
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccineGregory M Glenn, Gale Smith, Louis Fries, et al.
Pageof 2